HIMSS recognizes first 7 vendors to earn ConCert by HIMSS mark

HIMSS will recognize seven health IT vendors for developing ConCert by HIMSS™ certified products. Gaining the ConCert by HIMSS mark requires a rigorous testing program to demonstrate that the product is interoperable with other products and can enable the secure, reliable, efficent and seamless transfer of data within and across organizational and state boundaries.

The seven vendors are:

  • Caradigm
  • Cerner
  • Corepoint Health
  • iPatientCare
  • MEDfx
  • NextGen Healthcare
  • Qvera

Introduced at HIMSS15, ConCert by HIMSS offers a vendor-independent seal of approval for EHR, health information services provider (HISP) and health information exchange (HIE) systems. Governed by HIMSS, ConCert by HIMSS is built on the work of the EHR/HIE Interoperability Workgroup and IHE USA. ICSA Labs serves as the testing and certification body for this effort. Stella Technology designed the program’s Interoperability Test Tool.

“In less than a year, seven vendors have responded successfully to the exciting opportunity to advance products meeting Concert by HIMSS’ rigorous standards,” said Joyce Sensmeier, vice president, informatics, HIMSS North America. “As a result, their certified products will be in the spotlight at the HIMSS Interoperability Showcase’s Testing and Certification Vignette, where HIMSS16 attendees will be able to see firsthand how certified products facilitate data exchange leading to the best point-of-care decisions and most optimal patient outcomes.”

“The development of these seven certified products is another important stride toward health information exchange across health system and state boundaries,” said George Japak, managing director, ICSA Labs. “ICSA Labs looks forward to the growth of the Concert by HIMSS program as interoperability continues to climb by increasing numbers of patients and providers.”

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.